DC-CIK生物免疫治疗联合放疗在肝癌治疗中的临床效果

Clinical Efficacy of DC-CIK Immune Therapy Combined with Radiotherapy for Hepatocellular Carcinoma

目的观察DC-CIK生物免疫治疗联合放疗治疗肝癌的临床疗效。方法选取78例患者随机分为2组。2组患者均接受放射治疗,观察组在放疗的基础上联合DC-CIK生物免疫治疗。比较2组的临床治疗效果,观察患者治疗前后的免疫功能和生活质量,观察2组患者的不良反应的发生情况。结果观察组患者的治疗总有效率为80.05%,对照组为56.41%;观察组患者平均生存期为(23.8±7.4)个月,治疗组为(14.9±3.3)个月。2组患者的治疗有效率和生存期差异具有统计学意义(P<0.05)。经过治疗后,2组患者的KPS评分较治疗前明显好转(P<0.05);观察组患者的免疫功能较治疗前明显好转,具有统计学意义(P<0.05)。治疗后观察组患者的免疫功能和KPS评分明显高于对照组(P<0.05)。观察组5例(12.82%)患者出现不良反应,对照组4例(10.26%),差异无统计学意义(P>0.05)。结论DC-CIK生物免疫治疗联合放疗治疗肝癌的临床疗效较为显著,患者不良反应发生率较低,值得推广应用。

Objective To observe the clinical effect of DC-CIK immune therapy combined with radiotherapy for hepato-cellular carcinoma.Methods 78 cases of patients were randomly divided into 2 groups.All patients received radiation therapy , while the observation group was given additional DC-CIK immune therapy .Clinical effect of 2 groups were compared , immune function,quality of life and adverse reactions of the 2 groups before and after treatment of patients were observed .Results The total efficiency of the patients in the treatment group and the control group were 80.05%and 56.41%.The average survival time of patients in the observation group and the treatment group were (23.8 ±7.4) months and (14.9 ±3.3) months.The difference between effective rate and survival time of the 2 groups had statistical significance (P<0.05).After treatment,KPS score of two groups of patients significantly improved than before treatment (P<0.05),and the immune function of patients improved signifi-cantly than before treatment,with statistical significance (P<0.05).After treatment,immune function and KPS score in the ob-servation group were significantly higher than that of the control group (P<0.05).5 cases in the observation group (12.82%) had adverse reactions ,and 4 cases in the control group (10.26%) had adverse reactions ,the difference between the 2 groups had no statistical significance (P>0.05).Conclusion DC-CIK immune therapy combined with radiotherapy for hepatocellular car-cinoma has obvious clinical effect ,and incidence rate of the adverse reactions is lower .It is worthy of popularization and applica-tion.